<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intraperitoneal antibiotic dosing recommendations for continuous administration in adult patients on peritoneal dialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intraperitoneal antibiotic dosing recommendations for continuous administration in adult patients on peritoneal dialysis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Intraperitoneal antibiotic dosing recommendations for continuous administration in adult patients on peritoneal dialysis</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="15%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr class="border_bottom_thick highlight_gray_text"> <td> </td> <td class="subtitle1_left">Initial IP loading dose</td> <td class="subtitle1_left"> <p>Maintenance IP dose administered with all exchanges following a loading dose, if indicated</p> NOTE: <span style="font-weight: normal;">Intermittent regimens, which are listed in a separate table, are preferred for initial treatment in most patients with peritoneal dialysis-associated peritonitis. For additional information refer to legend below and UpToDate topic on microbiology and therapy of peritonitis in peritoneal dialysis.</span></td> </tr> <tr> <td class="subtitle2_left" colspan="3">Aminoglycosides</td> </tr> <tr> <td class="indent1" colspan="3">We do not administer IP aminoglycosides continuously</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Carbapenem</td> </tr> <tr> <td class="indent1">Imipenem-cilastatin<sup>*</sup></td> <td>250 mg/L dialysate</td> <td>50 mg/L dialysate</td> </tr> <tr> <td class="indent1">Meropenem</td> <td>None</td> <td>125 mg/L dialysate</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Cephalosporins</td> </tr> <tr> <td class="indent1">Cefazolin</td> <td>500 mg/L dialysate</td> <td>125 mg/L dialysate</td> </tr> <tr> <td class="indent1">Cefepime</td> <td>500 mg/L dialysate</td> <td>125 mg/L dialysate</td> </tr> <tr> <td class="indent1">Cefoperazone<sup>¶</sup></td> <td>500 mg/L dialysate</td> <td>62.5 to 125 mg/L dialysate</td> </tr> <tr> <td class="indent1">Ceftazidime</td> <td>500 mg/L dialysate</td> <td>125 mg/L dialysate</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Penicillins</td> </tr> <tr> <td class="indent1">Amoxicillin<sup>Δ</sup></td> <td>None</td> <td>150 mg/L dialysate</td> </tr> <tr> <td class="indent1">Ampicillin<sup>◊</sup></td> <td>None</td> <td>125 mg/L dialysate</td> </tr> <tr> <td class="indent1">Ampicillin-sulbactam<sup>§</sup></td> <td>750 to 1000 mg/L dialysate</td> <td>100 mg/L dialysate</td> </tr> <tr> <td class="indent1">Penicillin G</td> <td>50,000 units/L dialysate</td> <td>25,000 units/L dialysate</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Glycopeptides</td> </tr> <tr> <td class="indent1">Teicoplanin<sup>¶</sup></td> <td>400 mg in one bag</td> <td>20 mg/L dialysate</td> </tr> <tr> <td class="indent1">Vancomycin</td> <td>2 grams in one bag</td> <td>25 mg/L dialysate<sup>¥</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="3">Others</td> </tr> <tr> <td class="indent1">Aztreonam</td> <td>500 mg/L dialysate</td> <td>250 mg/L dialysate</td> </tr> <tr> <td class="indent1">Ciprofloxacin<sup>‡</sup></td> <td>None</td> <td>50 mg/L dialysate</td> </tr> <tr> <td class="indent1">Clindamycin</td> <td>None</td> <td>600 mg per bag</td> </tr> <tr> <td class="indent1">Daptomycin</td> <td>100 mg/L dialysate</td> <td>20 mg/L dialysate</td> </tr> <tr> <td class="indent1">Ofloxacin<sup>Δ‡</sup></td> <td>200 mg in one bag</td> <td>25 mg/L dialysate</td> </tr> <tr> <td class="indent1">Polymyxin B</td> <td>None</td> <td>300,000 units (30 mg) per bag</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Oral options that provide adequate levels within the peritoneum: <span style="font-weight: normal;">Refer to separately available table of intermittently administered antibiotics in peritoneal dialysis-associated peritonitis.</span></td> </tr> </tbody></table></div><div class="graphic_lgnd">This table shows the suggested dose of antibiotics for IP administration in <strong>all</strong> exchanges of peritoneal dialysate for continuous ambulatory peritoneal dialysis-associated peritonitis, without signs of systemic infection. Intermittent IP-administered regimens are preferred over the continuous regimens shown in this table for initial therapy and should be used for the duration of treatment of 2 to 3 weeks or more in patients who are responding clinically. In patients who are not improving on intermittent therapy with agent(s) that should be effective based on microbiologic data, it is reasonable to increase frequency of intermittent dosing or switch to the continuous IP dosing regimens shown in this table. Refer to UpToDate topic on microbiology and therapy of peritonitis in peritoneal dialysis for considerations in selection of antimicrobials and dosing strategy.</div><div class="graphic_footnotes"><p>IP: intraperitoneal.</p>
<p>* Dose is expressed as mg of imipenem.</p>
<p>¶ Not available in the United States.</p>
<p>Δ Solution for injection is not available in the United States.</p>
<p>◊ For enterococcal peritonitis, we avoid ampicillin because some in vitro data suggest that its activity against <em>Enterococcus</em> may be limited in peritoneal fluid.</p>
<p>§ Dose is expressed as total grams of ampicillin-sulbactam. Ampicillin-sulbactam is formulated in a 2:1 ratio (eg, 3 grams of ampicillin-sulbactam contains 2 g ampicillin and 1 g sulbactam).</p>
<p>¥ We do not check serum vancomycin levels. If the maintenance dose is 25 mg/L, the serum vancomycin level will not exceed 25 mg/L.</p>
‡ We generally avoid fluoroquinolones because they have significant adverse effects, increase the risk of <em>Clostridioides difficile</em> infection, and some have numerous drug interactions. Refer to UpToDate topic on microbiology and therapy of peritonitis in peritoneal dialysis.</div><div class="graphic_reference">Adapted from:
<ol>
<li>Li PK, Szeto CC, Piraino B, et al. Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. Perit Dial Int 2010; 30:393.</li>
<li>Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 2022; 42:110.</li>
</ol></div><div id="graphicVersion">Graphic 79841 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
